Marize Newnham is a neurological physiotherapist with a keen interest in early Parkinson’s and stroke rehabilitation. She spent over 15 years as a Senior Clinician in public and private hospitals and now works with individual, group and Zoom clients through her Melbourne-based private practice Regain Life Physiotherapy, and part-time in rehabilitation across Eastern Health public…
Catherine was a happily retired medical practitioner when in 2015, the threat of a knee replacement caused her to discover photobiomodulation and the work of University of Sydney’s Prof John Mitrofanis. She made a light device for her knee, and light hats for people with Parkinson’s disease, all with surprisingly good outcomes. In 2018 she…
Stephen Mullin is a Neurologist interested in how genetics can be used to develop new treatments and improve care for people with Parkinson’s. He ran the first genetically targeted clinical trial of a drug designed to slow down Parkinson’s and created pdfrontline.com, a UK internet based portal to allow people with Parkinson’s to undergo genetic…
Amy Amara, MD, PhD, is a physician scientist at the University of Alabama at Birmingham, Department of Neurology. She has fellowship training in both Movement Disorders and Sleep Medicine, with a particular interest in sleep dysfunction and other non-motor symptoms in patients with Parkinson’s disease (PD). Her main research focus includes investigation of non-pharmacological interventions,…
Professor Barran holds a Chair of Mass Spectrometry in the Department of Chemistry, is Associate Dean for Research Facilities and Director of the Michael Barber Centre for Collaborative Mass Spectrometry at the Manchester Institute of Biotechnology, The University of Manchester, UK. Her research interests include: Biological mass spectrometry; Instrument and technique development; Protein structure and…
Parkinson’s Research scientist. PhD (McGill, Canada), Post-Doc (Oregon), Faculty (Univ. Missouri). Returned to Australia to the Garvan Institute to study the molecular mechanisms of Parkinson’s Disease, Biomarkers, genetic contributions and the intent of slowing/stopping disease progression Conjoint/Adjunct Role(s): Conjoint Senior Lecturer, School of Biotechnology & Biomolecular Sciences, St Vincent’s Clinical School, UNSW Sydney Antony Cooper is…
Jon Roozenbeek is a postdoctoral fellow at the Department of Psychology at the University of Cambridge. His research focuses broadly on misinformation, online extremism, vaccine hesitancy, and the development of psychological “vaccines” against common misinformation techniques. His doctoral dissertation (2020) examined media discourse in the so-called “People’s Republics” of Donetsk and Luhansk in eastern Ukraine.
David Finkelstein is the head of the Parkinson’s Disease Laboratory at the Florey Institute of Neuroscience and Mental Health Physiologist and neurobiologist David Finkelstein is the head of the Parkinson’s Disease Laboratory at the Florey Institute of Neuroscience and Mental Health. In this role, he uses his skills and knowledge to investigate possible new medical…
Kenneth Marek is Distinguished Scientist at the Institute for Neurodegenerative Disorders. Dr Marek’s major research interests include identification of biomarkers for early detection, assessment of disease progression and development of new treatments for Parkinson’s disease, Alzheimer disease and related neurodegenerative disorders. He has authored numerous neurology and neuroscience publications on these topics. Dr. Marek is the…
Dr. Benzi Kluger is a Professor of Neurology and Medicine and the Director of the Palliative Care Research Center and the Neuropalliative Care Division at the University of Rochester. Dr. Kluger is a pioneer in the field of neuropalliative care, the application of palliative care approaches to improve the lives of persons living with neurologic…